Inclusion Criteria:

- Signed and dated IRB/EC-approved informed consent

- Age 18 years or older

- Histologically confirmed prostate adenocarcinoma

- Metastatic HRPC

- Received prior castration by orchidectomy and/or LH-RH agonist with or without
antiandrogen, antiandrogen withdrawal, monotherapy with estramustine, or other
hormonal agents.

- Tumor disease must be progressive after a first line using docetaxel based
chemotherapy, eventually in association with estramustine. Docetaxel based regimen
may have been interrupted and restarted. Patient must have either measurable (RECIST
criteria) or non-measurable (bone) disease and/or clinical progression (bone pain)
and/or biological progression (PSA Working Group criteria).

- Discontinuation from previous chemotherapy and/or radiation therapy at least 4 weeks
prior to treatment initiation

- Performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) scale

- Patient of child bearing potential must use effective contraception. Female partners
of treated patients with child bearing potential must use oral contraceptives or
intra uterine device (IUD)

- Life expectancy of at least 3 months

- Resolution of all acute toxic effects of any prior local treatment to NCI CTCAE grade
1

- Patients must have adequate organ functions defined

- Willingness and ability to comply with scheduled visits, treatment plans, laboratory
tests, and other study procedures

- Patient covered by the National Health System

Exclusion Criteria:

- Prior treatment with sunitinib or other antiangiogenic agent

- More than 1 line of chemotherapy

- External beam radiotherapy for ≥ 50% of bone marrow

- Uncontrolled hypertension (systolic blood pressure > 150 mm Hg or diastolic blood
pressure > 90 mm Hg despite optimal medical management)

- Any of the following within 12 months prior to treatment initiation: severe/unstable
angina, myocardial infarction, coronary artery bypass graft, symptomatic congestive
heart failure, thrombotic or embolic events such as cerebrovascular accident
including transient ischemic attack

- Ongoing cardiac dysrhythmias of grade 2, atrial fibrillation of any grade

- Treatment with anticonvulsant agents and treatment with therapeutic doses of
coumarin-derivative anticoagulants such as warfarin currently or within 2 weeks prior
to first day of Sunitinib administration. Low dose of warfarin for deep vein
thrombosis prophylaxis is permitted (up to 2 mg/day) and low molecular weight heparin
is allowed

- Any medical condition that might interfere with oral medication absorption

- Known or suspected brain metastasis, or carcinomatous meningitis, or spinal cord
compression

- Diagnosis of any second malignancy within the last 3 years, with the exception of
treated basal cell or squamous cell carcinoma and pT1/a bladder cancer with no
evidence of recurrent disease for 12 months

- Any acute or chronic medical or psychiatric disorder incompatible with the study

- Known human immunodeficiency virus or acquired immunodeficiency syndrome-related
illness

- Treatment with others investigational drugs or participation in another clinical
trial within the past 4 weeks, or concomitantly with this trial